Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast Details
Apogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company's website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
[email protected]
Media Contact:
Dan Budwick
1AB
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
FBI Probes Detroit Pistons' Malik Beasley Over Wire Fraud and Illegal Gambling
Federal authorities are investigating former Detroit Pistons guard Malik Beasley's alleged involvement in wire fraud, gambling, and illegal prop betting, according to ESPN. The allegations stem from Beasley's time playing for the Milwaukee Bucks during the 2023-2024 season, sources told the outlet, with the focus on 'unusually heavy betting interest on Beasley's statistics' starting in January 2024. A gambling industry source shared that one or more prominent U.S. sportsbooks noticed the activity. Advertisement The 18-month investigation is being led by the U.S. Attorney's Office for the Eastern District of New York, Beasley's lawyer Steve Haney told The Detroit News. 'It's a gambling investigation involving Malik. No criminal charges have been issued. It's nothing but an investigation and Malik is entitled to the presumption of innocence,' Haney said, per the outlet. The investigation has reportedly resulted in the Pistons withdrawing a three-year, $42 million contract offer to Beasley. While on the court, it appeared Beasley was fairing well. The free agent has played for six teams throughout his nine-career in the NBA and has earned nearly $60 million, including his recent one-year, $6 million deal with the Pistons, according to Spotrac. However, behind the scenes, a different story unfolded. Advertisement In April 2025, Hazan Sports Management Group Inc. sued Beasley, alleging he failed to repay a $650,000 cash advance for marketing revenue from using his name, image, and likeness. Hazan made 'a substantial investment of time, effort, and resources in a player with known issues (including and especially financial issues)…when they took him on as a client and provided him with a substantial marketing advance in anticipation of helping Beasley become one of the premier players at his position,' the lawsuit reads, per The Detroit News. The company added that when Beasley allegedly fired the firm, '…(Hazan) made several attempts to collect the full amount of the marketing advance but received little more than drips and drabs of sporadic payments and vague promises to repay the balance over time.' The firm is now seeking a minimum of $2.5 million, alleging that he failed to uphold their contract agreement. Advertisement Additional claims against Beasley include a lawsuit from The Stott apartments, stating he owes $7,355 in unpaid rent, as well as a $26,827 judgment won by a celebrity barbershop, Cairo Cuts, that provided him with a loan. Dentist Hassan Alshehabi of Delicate Smiles also won a $34,390 default judgment against Beasley related to a loan. The Detroit News reports Beasley's financial troubles total more than $8 million. 'I have been with Malik for a long time, I have seen a lot of people around him come and go, but I have stayed away from any of his financial management or mismanagement or decisions he would make with money,' Haney told the outlet. Haney clarified that he doesn't handle his client's finances and noted that while his goal is to connect his clients with top business experts, it's ultimately the client's decision to seek guidance. Advertisement The post FBI Probes Detroit Pistons' Malik Beasley Over Wire Fraud and Illegal Gambling appeared first on AfroTech. The post FBI Probes Detroit Pistons' Malik Beasley Over Wire Fraud and Illegal Gambling appeared first on AfroTech.
Yahoo
32 minutes ago
- Yahoo
Exclusive-WeightWatchers names new medical chief, plans to offer menopause therapy and support
By Amina Niasse NEW YORK (Reuters) -WeightWatchers will announce on Tuesday Dr. Kim Boyd as its chief medical officer, and plans for a new program to help women manage the transition into menopause and beyond, part of its growth strategy in emerging from bankruptcy. Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview that WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments. That includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The company says its model promoting balanced eating and exercise helps subscribers reduce gastrointestinal side effects from the medicines and lose more weight on Wegovy. 'We have the foundation, and we will continue to evolve our programming to show up in a way that matches best with the addition of medications,' Boyd said. WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications. "It's a different business model and these partnerships and relationships take a much longer period of time than dialing up some direct to consumer marketing or promotional models," Comonte said. The program for perimenopause, menopause and post-menopause will include access to prescription treatments such as hormone replacement therapy, as well as behavioral and nutritional support for members, a significant proportion of whom are women ages 40 to 60 years old, WeightWatchers said. More details will become available later this year, the company, also known as WW International, said. 'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' Boyd said. CHANGING WEIGHT LOSS MARKET Boyd previously served as national medical director at One Medical, a clinical business now owned by and later was chief medical officer at weight-management company Calibrate. Her appointment comes nearly a year after previous Chief Medical Officer Dr. Amy Meister stepped down. In the interim, WeightWatchers emerged from Chapter 11 bankruptcy, after struggling to compete with other online weight-management platforms selling cheaper, compounded versions of obesity treatments, including telehealth companies like Hims & Hers Health. The market for weight-management companies is changing since the U.S. Food and Drug Administration ordered an end to sales of compounded versions of Wegovy in late May. WeightWatchers last month announced a partnership with Novo Nordisk to sell Wegovy through the drugmaker's NovoCare pharmacy. Hims & Hers continues to offer smaller doses of compounded Wegovy than what is available from Novo, arguing they are providing a personalized medication that is not subject to the FDA ban. Industry analysts, however, have questioned whether that strategy will leave Hims vulnerable to legal challenges. Hims has said it also plans to expand into testosterone and menopause treatments as part of its growth strategy in the coming years. WeightWatchers has stopped selling compounded weight-loss drugs, and its partnership with Novo may prove more attractive to employer-sponsored health plans in the long run, Boyd said. "At the foundation of this is prescribing FDA-approved medications," Comonte said. 'We only prescribe branded drugs." A month's supply of Wegovy is listed at over $1,000 per month, but many people pay less through insurance. Cash-pay patients can access the treatment for $499 through NovoCare. 'For employers, some of them are finding value in these vendors like WeightWatchers... that give the members the lifestyle tools,' said Chantell Reagan, a senior director at advisory firm Willis Towers Watson. These strategies may help an employee sustain weight loss if they stop using a drug, she said. 'We are looking very closely at our employers that are using these programs and assessing the effectiveness.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
The stock-market rally is broadening beyond Big Tech. Will consumer stocks bounce back in the second half of the year?
After months of leadership by megacap technology stocks, Wall Street kicked off the second half of 2025 with a powerful, yet potentially healthier, shift in the U.S. stock market, as the rally has broadened. From cyclicals to small caps, more stocks have been joining the charge that has sent the S&P 500 SPX and the Nasdaq Composite COMP to new all-time highs, suggesting that this market's recovery from April lows may have deeper roots than many anticipated. 'Today is my 61st birthday': I have my ex-spouse's Social Security benefits. Should I retire at 65 and travel? 'I'm single': At 70, I have $500,000 in stocks and $220,000 in savings. How do I invest my $130,000 windfall? 'She's in a shaky marriage that could soon end': Will my daughter's husband get my IRA when I die? My wife and I are in our late 60s. Do I sell stocks to pay our $30,000 credit-card debt — or do it gradually over 3 years? I put my $500K inheritance into a joint account with my husband. Can I leave half of it to my son from a previous marriage? Investors have begun rotating out of richly valued technology names and into cyclical sectors when the calendar turned to the second half of the year. The S&P 500's materials sector XX:SP500.15 was the best performer among the large-cap index's 11 sectors last week, up 3.6%, while the S&P 500 only rose 1.7%. The financials XX:SP500.40 and energy XX:SP500.10 sectors also gained 2.4% and 2.1% in the same period, respectively, according to FactSet data. Small-cap stocks also have shown signs of rebounding in the second half. The benchmark Russell 2000 index RUT has popped 3.5% so far this month, outperforming other major large-cap equity indexes. The small-cap index on Thursday also closed in the green for 2025 for the first time since Feb. 20, according to Dow Jones Market Data. 'While the 'buy everything' approach worked really well off the April lows, and part of that was simply just a mean reversion trade after tech got asymmetrically punished … so going forward, stock selection is going to be more important and other areas of the market are starting to catch a bid,' said Talley Leger, chief market strategist for the Wealth Consulting Group. The broadening of the tech rally beyond the so-called Magnificent Seven cohort is a sign of 'a broader, healthier market,' he said. Meanwhile, some sectors that lagged in the year's first half could be poised for a meaningful rebound in the rest of 2025. The S&P 500's consumer-discretionary sector XX:SP500.25 was at the bottom of the large-cap index's 11 sectors in the first six months of 2025, off 4.2% to log its worst first-half performance in three years, according to FactSet data. However, a look beneath the surface shows the story wasn't so bleak: Many consumer-related stocks have held steady, and U.S. consumers might be in better shape than sector performance suggests. The S&P 500 Equal Weight Consumer Discretionary Index XX:SP500EW.25 — which gives equal value to all 51 stocks that are included in the sector, regardless of the size of the company — has actually risen 2.5% this year, according to FactSet data. Of course, Tesla Inc. TSLA — one of the largest-weighted stocks in the S&P 500's consumer discretionary sector — has been largely to blame. Comprising 18.6% of the total assets within the market-cap-weighted sector index, shares of Tesla have tumbled nearly 22% this year, as weak EV sales, lower demand, intensifying competition from other automakers and Elon Musk's political involvement have rattled investors. See: Opinion: Elon Musk takes us for fools as he renews his verbal assault on Trump Another megacap tech name — Inc. AMZN — accounts for roughly 42% of the weighting in the discretionary sector, but its shares have remained relatively steady, rising 1.8% year to date, according to FactSet data. To be sure, Tesla and Amazon stand on their own perch within the consumer-discretionary sector, which also includes restaurant chains, apparel, luxury goods and travel stocks. Among those are McDonald's Corp. MCD, Lululemon Athletica Inc. LULU and Airbnb Inc. ABNB, which all can rise in a resilient economy and labor market when consumers tend to spend more, but fall when unemployment rises. See: The June jobs report is grimy under the hood. Here's the down and dirty. The U.S. economy added a stronger-than-expected 147,000 jobs in June, and the unemployment rate ticked down to 4.1% from 4.2%, according to Bureau of Labor Statistics data released Thursday. Meanwhile, the University of Michigan's closely watched gauge of U.S. consumer sentiment rose to 60.5 in a preliminary June reading from 52.2 in the prior month. This was the first improvement in six months. The Wealth Consulting Group's Leger sees the previously negative consumer sentiment as a potential buying opportunity for the consumer-discretionary sector (see chart below). 'The connection between the University of Michigan consumer-sentiment index and the performance of the consumer-discretionary sector fell into the contrarian buy zone on our radar when everything was at its worst [in April]. Now they are rebounding off those lows, and sentiment or morale is improving,' he told MarketWatch via phone on Wednesday. In Leger's view, the surging stock market also adds to 'the wealth effect,' which could increase consumer spending power. That, along with the improving consumer sentiment, falling oil prices, cooling headline inflation and potential interest-rate cuts from the Federal Reserve later this year 'should release more money for spending on discretionary items,' and 'help brighten the earnings outlook' for the sector, he said. However, Marta Norton, chief investment strategist at Empower, said it's still too early to 'make heads or tails' of consumers' emotions, as even the potential tariff threat doesn't feel as concerning as it did when it first made headlines a few months ago. Americans cut spending in May after buying lots of new cars and other goods earlier in the year to beat U.S. tariffs, underscoring how ongoing trade wars are disrupting the economy. Personal spending fell 0.1% in May, the government said in a June 27 report. It was the first decline since January. 'I wouldn't describe the consumer as unhealthy at all,' Norton said, but added there has been a marginal deterioration this year. 'There is still a certain measure of uncertainty around what that trade policy ultimately looks like,' she said. That also casts a shadow over the long run for earnings of discretionary stocks. Yet despite recent weakness, the consumer-discretionary sector remains expensive on a price-to-forward-earnings (P/E) basis. The forward P/E multiple of the discretionary sector, calculated by dividing its current price by Wall Street analysts' consensus estimate for its earnings per share (EPS) for the next 12 months, was pegged at 29.07 as of Wednesday afternoon, up from around 22.56 on April 8. Furthermore, the equal-weighted version of the discretionary index was trading at 17.57 times forward P/E, compared with 13.7 in early April, according to FactSet. When you add in that the sector's not necessarily cheap, and that tariff headwinds remain, Norton said it looks tough to see a catalyst for meaningful moves higher for consumer-discretionary stocks. U.S. stocks finished higher on Thursday as investors digested the June employment report. The Dow Jones Industrial Average DJIA jumped nearly 0.8%, ending only 0.4% off its prior record. The S&P 500 ended up 0.8%, while the Nasdaq Composite gained 1%, with both scoring fresh record closes, according to FactSet data. Major U.S. stock exchanges were closed on Friday for the July 4 holiday. 'I do all the yard work, cooking and cleaning': I live with my daughter and her lazy boyfriend. She wants me to buy her house. Do I say yes? The stock-market rally is broadening beyond Big Tech. Will consumer stocks bounce back in the second half of the year? My job is offering me a payout. Should I take a $61,000 lump sum — or $355 a month for life? 'Finance makes me break out in hives': I inherited $240K from my parents. Do I pay off my $258K mortgage and give up my job? My life partner is 18 years my senior. He wants to leave his $4.5 million fortune to me — not his two kids. Do we tell them? Sign in to access your portfolio
